Redeye updates its outlook on Stille following a report that missed expectations due to temporary supply constraints, portfolio rationalisation in the surgical instrument business unit, and postponed deliveries in the table segment. While making slight downward revisions, we maintain a positive view of the case and see that the valuation is undemanding.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/